Literature DB >> 12050233

A family of autosomal dominant hypocalcemia with a positive correlation between serum calcium and magnesium: identification of a novel gain of function mutation (Ser(820)Phe) in the calcium-sensing receptor.

Terumasa Nagase1, Takehiko Murakami, Toshihiko Tsukada, Ryuichi Kitamura, Noriko Chikatsu, Hiroki Takeo, Nobuki Takata, Hiroko Yasuda, Seiji Fukumoto, Yuji Tanaka, Naokazu Nagata, Ken Yamaguchi, Takuhiko Akatsu, Michiko Yamamoto.   

Abstract

To date about 20 activating mutations in the calcium-sensing receptor (CaR) gene have been identified to cause autosomal dominant hypocalcemia (ADH) or sporadic hypoparathyroidism. We report a novel activating mutation in the CaR gene in a Japanese family with ADH. The proband, a 15-yr-old boy, and 5 other patients in 3 generations were asymptomatic, except for the proband's grandmother who had a history of seizures. They showed mild hypocalcemia (1.68-1.98 mmol/liter) with normal urinary calcium excretion and low normal serum PTH levels. Their serum magnesium concentrations were below normal in 3 adults and within the normal range in 3 teenagers. There was a significant positive correlation (r = 0.90; P < 0.05) between the serum calcium and magnesium concentrations of 6 affected members. Nucleotide sequencing revealed that the proband had a known polymorphism (Gly(990)Arg) and a novel heterozygous mutation substituting phenylalanine for serine at codon 820 (Ser(820)Phe) in the sixth transmembrane helix of the CaR. In other family members, the Ser(820)Phe mutation cosegregated with hypocalcemia. The mutation was not detected in 50 control subjects. The Gly(990)Arg polymorphism was observed in 8 of 9 family members with or without hypocalcemia and in 36 of 50 controls. The sensitivity of the Ser(820)Phe mutant CaR to calcium was assessed using transiently transfected HEK293 cells and measuring the increases in intracellular Ca(2+) concentrations in response to the changes in extracellular Ca(2+). The concentration-response curve of the mutant receptor was left-shifted, and its EC(50) (2.5 mM) was significantly (P < 0.05) lower than that of the wild-type CaR (3.3 mM). We conclude that the Ser(820)Phe mutation in the CaR caused ADH in this family. The positive correlation between serum calcium and magnesium levels observed in this family may support the concept that renal CaR acts as a magnesium sensor as well as a calcium sensor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050233     DOI: 10.1210/jcem.87.6.8531

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Calcium-sensing receptor residues with loss- and gain-of-function mutations are located in regions of conformational change and cause signalling bias.

Authors:  Caroline M Gorvin; Morten Frost; Tomas Malinauskas; Treena Cranston; Hannah Boon; Christian Siebold; E Yvonne Jones; Fadil M Hannan; Rajesh V Thakker
Journal:  Hum Mol Genet       Date:  2018-11-01       Impact factor: 6.150

2.  A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism.

Authors:  Masaaki Shiohara; Tetsuo Mori; Bai Mei; Edward M Brown; Tomoyuki Watanabe; Toshiyuki Yasuda
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 3.  Mineral metabolism and bone disease after bariatric surgery and ways to optimize bone health.

Authors:  Dave H Schweitzer
Journal:  Obes Surg       Date:  2007-11       Impact factor: 4.129

Review 4.  Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR.

Authors:  Daniela Riccardi; Brenda A Finney; William J Wilkinson; Paul J Kemp
Journal:  Pflugers Arch       Date:  2009-05-30       Impact factor: 3.657

5.  CaSR-mediated interactions between calcium and magnesium homeostasis in mice.

Authors:  Stephen J Quinn; Alex R B Thomsen; Ogo Egbuna; Jian Pang; Khanjan Baxi; David Goltzman; Martin Pollak; Edward M Brown
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-29       Impact factor: 4.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.